MD20160102A2 - Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei - Google Patents

Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei

Info

Publication number
MD20160102A2
MD20160102A2 MDA20160102A MD20160102A MD20160102A2 MD 20160102 A2 MD20160102 A2 MD 20160102A2 MD A20160102 A MDA20160102 A MD A20160102A MD 20160102 A MD20160102 A MD 20160102A MD 20160102 A2 MD20160102 A2 MD 20160102A2
Authority
MD
Moldova
Prior art keywords
chromene
pyridopyrazinediones
tetrahydrocyclopropa
gamma
secretase modulators
Prior art date
Application number
MDA20160102A
Other languages
English (en)
Russian (ru)
Inventor
ЭНД Кристофер Уильям АМ
Джон Майкл Хамфри
Дуглас Скотт Джонсон
Грегори Уэйн КАУФМАН
Мартин Янцзин ПЕТТЕРССОН
Даника Антония РАНКИЦ
Антония Фредерик СТЕПАН
Патрик Роберт Верхоест
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52815058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD20160102(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of MD20160102A2 publication Critical patent/MD20160102A2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Sunt dezvăluiţi compuşi cu Formula I şi sărurile farmaceutic acceptabile ale acestoraunde X, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6, R7, y şi z sunt aşa cum sunt definiţi în descriere. Sunt de asemenea dezvăluite compoziţii farmaceutice, metode de tratament, metode de sinteză şi produşi intermediari. Aceşti compuşi au proprietăţi de modulatori ai γ-secretazei şi pot fi utili în tratamentul maladiilor neurodegenerative şi/sau neurologice, aşa ca boala Alzheimer şi sindromul Down.
MDA20160102A 2014-04-01 2015-03-18 Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei MD20160102A2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461973436P 2014-04-01 2014-04-01
PCT/IB2015/051988 WO2015150957A1 (en) 2014-04-01 2015-03-18 Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators

Publications (1)

Publication Number Publication Date
MD20160102A2 true MD20160102A2 (ro) 2017-04-30

Family

ID=52815058

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20160102A MD20160102A2 (ro) 2014-04-01 2015-03-18 Cromen şi 1,1a,2,7b-tetrahidrociclopropa[c]cromen piridopirazindione ca modulatori ai gama-secretazei

Country Status (30)

Country Link
US (2) US20150274721A1 (ro)
EP (1) EP3126361B1 (ro)
JP (1) JP6643247B2 (ro)
KR (1) KR101886945B1 (ro)
CN (1) CN106211770B (ro)
AP (1) AP2016009465A0 (ro)
AR (1) AR099874A1 (ro)
AU (1) AU2015242330B2 (ro)
BR (1) BR112016022519A8 (ro)
CA (1) CA2944308A1 (ro)
CL (1) CL2016002422A1 (ro)
CR (1) CR20160454A (ro)
CU (1) CU20160140A7 (ro)
DK (1) DK3126361T3 (ro)
DO (1) DOP2016000266A (ro)
EA (1) EA031419B1 (ro)
EC (1) ECSP16078289A (ro)
ES (1) ES2759277T3 (ro)
HK (1) HK1231481A1 (ro)
IL (1) IL248154B (ro)
MD (1) MD20160102A2 (ro)
MX (1) MX369074B (ro)
NI (1) NI201600149A (ro)
PE (1) PE20161364A1 (ro)
PH (1) PH12016501864A1 (ro)
SG (1) SG11201607465UA (ro)
TW (1) TWI568733B (ro)
UY (1) UY36054A (ro)
WO (1) WO2015150957A1 (ro)
ZA (1) ZA201606252B (ro)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2016125048A1 (en) * 2015-02-03 2016-08-11 Pfizer Inc. Novel cyclopropabenzofuranyl pyridopyrazinediones
CN106580997B (zh) * 2016-12-09 2018-01-19 张田 一种治疗先兆流产的药物组合物
KR20190098998A (ko) 2016-12-16 2019-08-23 파이프라인 테라퓨틱스, 아이엔씨. 달팽이관 시냅스질환의 치료 방법
KR102672512B1 (ko) * 2018-09-12 2024-06-10 노파르티스 아게 항바이러스 피리도피라진디온 화합물
CN110907542A (zh) * 2018-09-17 2020-03-24 复旦大学 一种液质联用检测唾液中司来吉兰及其代谢物的方法
JP7413346B2 (ja) 2019-03-06 2024-01-15 第一三共株式会社 ピロロピラゾール誘導体
JP7417715B2 (ja) 2019-09-26 2024-01-18 ノバルティス アーゲー 抗ウイルスピラゾロピリジノン化合物
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
WO2024084360A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1308461A3 (en) 1993-01-25 2004-02-11 Takeda Chemical Industries, Ltd. Antibodies to beta-amyloids or their derivatives and use thereof
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
AU743827B2 (en) 1997-04-09 2002-02-07 Intellect Neurosciences, Inc. Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
AU4178601A (en) 2000-02-24 2001-09-03 Univ Washington Humanized antibodies that sequester abeta peptide
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
CA2427661C (en) 2000-11-03 2013-05-28 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
CA2451998A1 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
KR101030629B1 (ko) * 2002-02-28 2011-04-20 미쯔비시 웰 파마 가부시키가이샤 헤테로아릴 치환된 2-피리디닐 및2-피리미디닐-6,7,8,9-테트라히드로피리미도[1,2-ａ]피리미딘-4-온 유도체
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
PL377769A1 (pl) 2002-10-09 2006-02-20 Rinat Neuroscience Corp. Sposób leczenia choroby Alzheimera z zastosowaniem przeciwciał skierowanych przeciw peptydowi beta amyloidu i ich kompozycje
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
EP1638935A1 (en) 2003-06-19 2006-03-29 Pfizer Products Inc. Nk1 antagonist
US20070031416A1 (en) 2003-09-09 2007-02-08 Takeda Pharmaceutical Company Limited Use of antibody
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
BRPI0507374A (pt) 2004-02-02 2007-07-10 Pfizer Prod Inc moduladores do receptor de histamina-3
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
SG190665A1 (en) 2004-07-30 2013-06-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
EP1827493A4 (en) 2004-12-22 2009-09-30 Univ St Louis USE OF ANTI-ABETA ANTIBODIES FOR TREATING TRAUMATIC BRAIN INJURY
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
CA2608018C (en) 2005-05-12 2010-07-13 Pfizer Inc. Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
CA2608672A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
ATE488496T1 (de) 2005-06-22 2010-12-15 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
CA2624625A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
US20090163482A1 (en) 2006-03-13 2009-06-25 Mchardy Stanton Furst Tetralines antagonists of the h-3 receptor
AP2408A (en) 2006-04-21 2012-05-30 Pfizer Prod Inc Pyridine[3,4-B]pyrazinones.
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
MX2009007782A (es) 2007-01-22 2009-07-31 Pfizer Prod Inc Sal de tosilato de un compuesto terapeutico y composiciones farmaceuiticas de la misma.
JP2012506857A (ja) * 2008-10-23 2012-03-22 メルク・シャープ・エンド・ドーム・コーポレイション 縮合複素環式ｍ１受容体ポジティブアロステリック調節因子
JP5767393B2 (ja) * 2011-03-31 2015-08-19 ファイザー・インク 新規二環式ピリジノン
US9181245B2 (en) * 2012-05-16 2015-11-10 Janssen Pharmaceuticals, Inc. Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease
UA110688C2 (uk) * 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
KR102171710B1 (ko) * 2013-01-17 2020-10-30 얀센 파마슈티카 엔.브이. 감마 세크레타제 조절 인자로서의 신규 치환 피리도-피페라지논 유도체
WO2015049616A1 (en) * 2013-10-04 2015-04-09 Pfizer Inc. Novel bicyclic pyridinones as gamma-secretase modulators

Also Published As

Publication number Publication date
SG11201607465UA (en) 2016-10-28
CA2944308A1 (en) 2015-10-08
UY36054A (es) 2015-10-30
KR20160137635A (ko) 2016-11-30
IL248154A0 (en) 2016-11-30
MX2016012904A (es) 2016-12-07
TWI568733B (zh) 2017-02-01
JP2017512803A (ja) 2017-05-25
US20150274721A1 (en) 2015-10-01
ES2759277T3 (es) 2020-05-08
IL248154B (en) 2020-09-30
US20170166566A1 (en) 2017-06-15
AP2016009465A0 (en) 2016-09-30
EP3126361B1 (en) 2019-11-06
PE20161364A1 (es) 2016-12-25
ZA201606252B (en) 2018-05-30
MX369074B (es) 2019-10-28
AU2015242330A1 (en) 2016-09-22
CU20160140A7 (es) 2017-02-02
EA201600619A1 (ru) 2017-03-31
BR112016022519A8 (pt) 2018-03-06
TW201540716A (zh) 2015-11-01
NI201600149A (es) 2016-11-18
BR112016022519A2 (pt) 2017-08-15
ECSP16078289A (es) 2017-02-24
CN106211770B (zh) 2018-02-06
DOP2016000266A (es) 2016-11-15
DK3126361T3 (da) 2020-01-02
CN106211770A (zh) 2016-12-07
AR099874A1 (es) 2016-08-24
AU2015242330B2 (en) 2017-08-17
EP3126361A1 (en) 2017-02-08
KR101886945B1 (ko) 2018-08-08
CL2016002422A1 (es) 2017-02-03
PH12016501864A1 (en) 2016-12-19
WO2015150957A1 (en) 2015-10-08
EA031419B1 (ru) 2018-12-28
JP6643247B2 (ja) 2020-02-12
HK1231481A1 (zh) 2017-12-22
CR20160454A (es) 2016-12-06

Similar Documents

Publication Publication Date Title
PH12016501864A1 (en) Chromene and 1, 1a, 2, 7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
PH12017500711A1 (en) Compositions and methods for treating cns disorders
PH12016502504A1 (en) Mnk inhibitors and methods related thereto
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
MX2019014292A (es) Anillos 5-5 fusionados como inhibidores c5a.
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
PH12017500595B1 (en) Aldosterone synthase inhibitors
PH12017501369A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
PH12017500089A1 (en) Aldosterone synthase inhibitors
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators
MX2016008968A (es) Compuestos organicos.
PH12017501134A1 (en) Fumagillol derivatives
PH12019502792A1 (en) Tetrahydropyridopyrazine modulators of gpr6
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.
IN2013MU03838A (ro)

Legal Events

Date Code Title Description
FA9A Abandonment or withdrawal of application (patent for invention)